Skip to main content
. 2010 Dec 2;286(9):7641–7647. doi: 10.1074/jbc.M110.185488

FIGURE 2.

FIGURE 2.

HDAC1 modifications significantly change HDAC1 mobility. A, FRAP analysis of the GFP-tagged HDAC1 6R mutant at the MMTV array before and after dexamethasone induction. The lysine-to-arginine mutant of HDAC1, which mimics unmodified HDAC1, exhibited accelerated mobility identical to the mobility of wild-type HDAC1 at early time points (30–60 min) upon dexamethasone treatment. The mobility did not change throughout the induction cycle. B, the GFP-tagged HDAC1 6R mutant was enriched at the MMTV locus marked by ChFP-NF1A1.1 in both induced and uninduced cells. Dex, dexamethasone. C, FRAP analysis of the GFP-tagged HDAC1 6Q mutant at the MMTV array before and after dexamethasone induction. The lysine-to-glutamine mutant of HDAC1, which mimics acetylated HDAC1, exhibited retarded mobility identical to the mobility of wild-type HDAC1 in the uninduced state or at later time points (60–120 min) upon dexamethasone treatment. The mobility did not change throughout the induction cycle. D, the GFP-tagged HDAC1 6Q mutant colocalized with ChFP-NF1A1.1 at the array locus in both induced and uninduced cells. The data are means ± S.E. from three independent experiments (n ≥15 cells).